Kawai Kento, Uchiyama Masateru, Hester Joanna, Wood Kathryn, Issa Fadi
Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Level 6, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Hum Immunol. 2018 May;79(5):294-303. doi: 10.1016/j.humimm.2017.12.013. Epub 2017 Dec 27.
Regulatory T cells (Tregs) are critical mediators of immune homeostasis and hold significant promise in the quest for transplantation tolerance. Progress has now reached a critical threshold as techniques for production of clinical therapies are optimised and Phase I/II clinical trials are in full swing. Initial safety and efficacy data are being reported, with trials assessing a number of different strategies for the introduction of Treg therapy. It is now more crucial than ever to elucidate further the function and behaviour of Tregsin vivoand ensure safe delivery. This review will discuss the current state of the art and future directions in Treg therapy.
调节性T细胞（Tregs）是免疫稳态的关键介质，在寻求移植耐受方面具有巨大潜力。随着临床治疗生产技术的优化以及I/II期临床试验的全面展开，进展现已达到关键节点。初步的安全性和有效性数据正在公布，多项试验正在评估引入Treg治疗的不同策略。现在，比以往任何时候都更迫切需要进一步阐明Tregs在体内的功能和行为，并确保安全递送。本综述将讨论Treg治疗的当前技术水平和未来方向。
